We connect all commercially available laboratories that offer state-of-art next-generation sequencing technology
Science Park, HONG KONG
The name ‘Sanomics’ is derived from the word of Sanguis, the Latin word for blood, and genomics, which stands for the study of genes.
Since the launch of Sanomics, “Patient First” has always been our principle. Putting patients’ needs as our top priority, we strive to revolutionize current cancer treatments by providing safe and efficient liquid-based and tissue-based genomic tests to patients. We aim to provide easy and convenient access to our services and help doctors decide personalized cancer solutions for patients.
Our work offers more than information; it can inspire hope in patients, families, friends, physicians, and caregivers.
Through constant innovation, we can make breakthroughs to help achieve improved outcomes for more individuals living with cancer. That’s why we foster a collaborative culture that motivates us to do our best work and be a partner in every patient's journey.
Our approach combines genomic profile products and data services to generate insights that can help doctors match patients to more treatment options and help accelerate the development of new therapies.
ACT Genomics is a world-leading cancer solution provider. We offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. We combine experts of tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. Through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings, we are dedicated to turning every cancer patient’s genetic information into actionable resolutions.